

Patient Information Leaflet for *SURGIFLO™ Haemostatic Matrix*

This leaflet has information about SURGIFLO™ Haemostatic Matrix, a product used to stop bleeding during your recent surgery. It does not contain all the information and if you have any questions, please talk to your healthcare team. All products have risks and benefits. Follow your healthcare team's advice even if it differs from what is in this leaflet. Please read this leaflet carefully and keep it in a safe place so you may refer to it in the future if needed.

Intended use

SURGIFLO™ Haemostatic Matrix is used in surgical procedures (other than those related to the eyes) as an aid to stop a bleeding when ligature and other conventional methods to stop a bleeding are ineffective or impractical. Only the minimum amount of SURGIFLO™ Haemostatic Matrix needed to stop a bleeding should be used.

Product Description

SURGIFLO™ Haemostatic Matrix is a flowable gelatin matrix which is made of porcine gelatin. It provides an environment for cells in the blood to join and stick together, building on the natural blood clotting processes to stop bleeding.

Expected product Lifetime

SURGIFLO™ Haemostatic Matrix has been applied during your surgery, and excess of SURGIFLO® Hemostatic Matrix has been removed by the surgeon. Remains of SURGIFLO™ Hemostatic Matrix is completely absorbed by the body within 4-6 weeks.

Symptoms after use of SURGIFLO® Haemostatic Matrix you should be aware of

Always contact your doctor or medical team if you have any signs of infection, swelling, or pain.

Adverse reactions

There is always a risk of adverse reactions with the use of any type of medical products. Some reactions could be due to your overall health condition and some reactions could be related to just having the surgery. Some reactions could be related to the product used during surgery. If any questions please contact your medical team.

Adverse events

In rare cases hypersensitivity or allergic reactions towards gelatin may occur. If any questions please contact your medical team.

Reporting Adverse Effects

If you wish to report any adverse effects you believe are a result of use of SURGIFLO® Haemostatic Matrix during your recent surgery, please speak with your medical team or

DIR 14039| Rev:1

report the information to Johnson & Johnson Medical Product Safety Department at productsafetyjjmanz@its.jnj.com or the Therapeutic Goods Administration at <https://www.tga.gov.au>

For access to this leaflet, please visit: <https://www.jnjmedicaldevices.com/en-AU/patient-information-leaflets>

Sponsor

Johnson & Johnson Medical Pty Ltd

1-5 Khartoum Rd, North Ryde, NSW 2113

Tel: 1300 562 711

TV-TEC-216734

Revision: 01

Date of Revision: Nov 2021